NovaMedica is starting construction of R&D Center for drug development using nanotechnologies

Print 15 December 2015

Moscow, December, 15, 2015 – NovaMedica, a Russian pharmaceutical company, is starting construction of R&D Center for innovative drug development and pilot production in Moscow. This Center will include laboratories and production areas equipped with state-of-the-art process equipment that has never been used in the Russian pharmaceutical industry before. The total investments are estimated approximately $15 million.

The main task of NovaMedica’s technology division will be drug development using new technology platforms, including nanotechnologies. “We are focusing on the development of innovative drug forms that provide controlled API bioavailability or combine previously incompatible APIs”, notes Mikhail Getman, NovaMedica’s Vice President of Pharmaceutical Operations. “Thereby, the developed products will have new potential applications and will be much better efficacy and safety than many current product. NovaMedica is the first company on this way forward”.

NovaMedica’s R&D Center is planned to be located at Technopolis Moscow. The laboratory capacities of will allow NovaMedica to run 15 R&D projects per year. The pilot production capacities will allow NovaMedica to manufacture up to 80 million doses per year. The R&D Center will create 35 R&D jobs. The R&D Center will be using 1600 sq. m. of space.

“Creation of a modern R&D center is an important input into development of R&D industry and a link in the chain of import substitution process in any high-tech industry”, commented Vladimir Gurdus, CEO of RMI Partners, managing company of NovaMedica. “Moreover, all innovative developments of NovaMedica will have patentable IP potential on a global level – we are planning to commercialize them not only in Russia but abroad as well.”

______________

Background information:  

NovaMedica is a Russian pharmaceutical company, established in 2012 by DRI Holdings Limited, a portfolio company of Domain Associates LLC, and RUSNANO, a Russian investment corporation, which implements the state policy on development of high-technology fields. The company’s strategy focuses on search, registration, and localization in Russia of intellectual property rights for innovative drugs and technologies, as well as development of a new high-technology pharmaceutical GMP manufacture. More details at: www.novamedica.com 

Return